317 related articles for article (PubMed ID: 11493435)
1. T-cell--depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: induction of graft-versus-myeloma effect.
Alyea E; Weller E; Schlossman R; Canning C; Webb I; Doss D; Mauch P; Marcus K; Fisher D; Freeman A; Parikh B; Gribben J; Soiffer R; Ritz J; Anderson K
Blood; 2001 Aug; 98(4):934-9. PubMed ID: 11493435
[TBL] [Abstract][Full Text] [Related]
2. Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant.
Alyea EP; Soiffer RJ; Canning C; Neuberg D; Schlossman R; Pickett C; Collins H; Wang Y; Anderson KC; Ritz J
Blood; 1998 May; 91(10):3671-80. PubMed ID: 9573003
[TBL] [Abstract][Full Text] [Related]
3. Comparative outcomes of T-cell-depleted and non-T-cell-depleted allogeneic bone marrow transplantation for chronic myelogenous leukemia: impact of donor lymphocyte infusion.
Sehn LH; Alyea EP; Weller E; Canning C; Lee S; Ritz J; Antin JH; Soiffer RJ
J Clin Oncol; 1999 Feb; 17(2):561-8. PubMed ID: 10080600
[TBL] [Abstract][Full Text] [Related]
4. Donor T-lymphocyte infusion for unrelated allogeneic bone marrow transplantation with CD3+ T-cell-depleted graft.
Lee CK; deMagalhaes-Silverman M; Hohl RJ; Hayashi M; Buatti J; Wen BC; Schlueter A; Strauss RG; Gingrich RD
Bone Marrow Transplant; 2003 Jan; 31(2):121-8. PubMed ID: 12621494
[TBL] [Abstract][Full Text] [Related]
5. T-cell depletion plus salvage immunotherapy with donor leukocyte infusions as a strategy to treat chronic-phase chronic myelogenous leukemia patients undergoing HLA-identical sibling marrow transplantation.
Drobyski WR; Hessner MJ; Klein JP; Kabler-Babbitt C; Vesole DH; Margolis DA; Keever-Taylor CA
Blood; 1999 Jul; 94(2):434-41. PubMed ID: 10397710
[TBL] [Abstract][Full Text] [Related]
6. CD6-depleted allogeneic bone marrow transplantation for acute leukemia in first complete remission.
Soiffer RJ; Fairclough D; Robertson M; Alyea E; Anderson K; Freedman A; Bartlett-Pandite L; Fisher D; Schlossman RL; Stone R; Murray C; Freeman A; Marcus K; Mauch P; Nadler L; Ritz J
Blood; 1997 Apr; 89(8):3039-47. PubMed ID: 9108425
[TBL] [Abstract][Full Text] [Related]
7. Immunologic effects of prophylactic donor lymphocyte infusion after allogeneic marrow transplantation for multiple myeloma.
Bellucci R; Alyea EP; Weller E; Chillemi A; Hochberg E; Wu CJ; Canning C; Schlossman R; Soiffer RJ; Anderson KC; Ritz J
Blood; 2002 Jun; 99(12):4610-7. PubMed ID: 12036895
[TBL] [Abstract][Full Text] [Related]
8. Changes in T cell receptor repertoire associated with graft-versus-tumor effect and graft-versus-host disease in patients with relapsed multiple myeloma after donor lymphocyte infusion.
Orsini E; Alyea EP; Schlossman R; Canning C; Soiffer RJ; Chillemi A; Neuberg D; Anderson KC; Ritz J
Bone Marrow Transplant; 2000 Mar; 25(6):623-32. PubMed ID: 10734296
[TBL] [Abstract][Full Text] [Related]
9. Reduced-intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: limited efficacy of graft-versus-tumor activity.
Peggs KS; Mackinnon S; Williams CD; D'Sa S; Thuraisundaram D; Kyriakou C; Morris EC; Hale G; Waldmann H; Linch DC; Goldstone AH; Yong K
Biol Blood Marrow Transplant; 2003 Apr; 9(4):257-65. PubMed ID: 12720218
[TBL] [Abstract][Full Text] [Related]
10. Long-term follow-up of T cell-depleted allogeneic bone marrow transplantation in refractory multiple myeloma: importance of allogeneic T cells.
Huff CA; Fuchs EJ; Noga SJ; O'Donnell PV; Ambinder RF; Diehl L; Borrello I; Vogelsang GB; Miller CB; Flinn IA; Brodsky RA; Marcellus D; Jones RJ
Biol Blood Marrow Transplant; 2003 May; 9(5):312-9. PubMed ID: 12766881
[TBL] [Abstract][Full Text] [Related]
11. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors.
Soiffer RJ; Mauch P; Fairclough D; Alyea E; Anderson K; Fisher D; Freedman A; Bartlett-Pandite L; Robertson M; Schlossman R; Gollob J; Marcus K; Murray C; Kuhlman C; Freeman A; Nadler L; Ritz J
Biol Blood Marrow Transplant; 1997 Apr; 3(1):11-7. PubMed ID: 9209736
[TBL] [Abstract][Full Text] [Related]
12. Intentional induction of mixed chimerism and achievement of antitumor responses after nonmyeloablative conditioning therapy and HLA-matched donor bone marrow transplantation for refractory hematologic malignancies.
Spitzer TR; McAfee S; Sackstein R; Colby C; Toh HC; Multani P; Saidman S; Weyouth DW; Preffer F; Poliquin C; Foley A; Cox B; Andrews D; Sachs DH; Sykes M
Biol Blood Marrow Transplant; 2000; 6(3A):309-20. PubMed ID: 10905768
[TBL] [Abstract][Full Text] [Related]
13. Complete response to donor lymphocyte infusion in multiple myeloma is associated with antibody responses to highly expressed antigens.
Bellucci R; Wu CJ; Chiaretti S; Weller E; Davies FE; Alyea EP; Dranoff G; Anderson KC; Munshi NC; Ritz J
Blood; 2004 Jan; 103(2):656-63. PubMed ID: 14563636
[TBL] [Abstract][Full Text] [Related]
14. Partial T cell-depleted allogeneic stem cell transplantation following reduced-intensity conditioning creates a platform for immunotherapy with donor lymphocyte infusion and recipient dendritic cell vaccination in multiple myeloma.
Levenga H; Schaap N; Maas F; Esendam B; Fredrix H; Greupink-Draaisma A; de Witte T; Dolstra H; Raymakers R
Biol Blood Marrow Transplant; 2010 Mar; 16(3):320-32. PubMed ID: 19835972
[TBL] [Abstract][Full Text] [Related]
15. Expansion of tumor-specific CD8+ T cell clones in patients with relapsed myeloma after donor lymphocyte infusion.
Orsini E; Bellucci R; Alyea EP; Schlossman R; Canning C; McLaughlin S; Ghia P; Anderson KC; Ritz J
Cancer Res; 2003 May; 63(10):2561-8. PubMed ID: 12750280
[TBL] [Abstract][Full Text] [Related]
16. [Allogeneic bone marrow transplantation for refractory multiple myeloma: presence of a graft-versus-myeloma effect].
Nawa Y; Noguchi T; Kojima K; Hara M
Rinsho Ketsueki; 2001 Jun; 42(6):481-7. PubMed ID: 11505527
[TBL] [Abstract][Full Text] [Related]
17. Randomized trial of CD8+ T-cell depletion in the prevention of graft-versus-host disease associated with donor lymphocyte infusion.
Soiffer RJ; Alyea EP; Hochberg E; Wu C; Canning C; Parikh B; Zahrieh D; Webb I; Antin J; Ritz J
Biol Blood Marrow Transplant; 2002; 8(11):625-32. PubMed ID: 12463482
[TBL] [Abstract][Full Text] [Related]
18. A new strategy for treatment of malignant tumor: intra-bone marrow-bone marrow transplantation plus CD4- donor lymphocyte infusion.
Suzuki Y; Adachi Y; Minamino K; Zhang Y; Iwasaki M; Nakano K; Koike Y; Ikehara S
Stem Cells; 2005 Mar; 23(3):365-70. PubMed ID: 15749931
[TBL] [Abstract][Full Text] [Related]
19. Prevention of graft-versus-host disease by selective depletion of CD6-positive T lymphocytes from donor bone marrow.
Soiffer RJ; Murray C; Mauch P; Anderson KC; Freedman AS; Rabinowe SN; Takvorian T; Robertson MJ; Spector N; Gonin R
J Clin Oncol; 1992 Jul; 10(7):1191-200. PubMed ID: 1607923
[TBL] [Abstract][Full Text] [Related]
20. Impact of prophylactic donor leukocyte infusions on mixed chimerism, graft-versus-host disease, and antitumor response in patients with advanced hematologic malignancies treated with nonmyeloablative conditioning and allogeneic bone marrow transplantation.
Dey BR; McAfee S; Colby C; Sackstein R; Saidman S; Tarbell N; Sachs DH; Sykes M; Spitzer TR
Biol Blood Marrow Transplant; 2003 May; 9(5):320-9. PubMed ID: 12766882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
